ESMO Targeted Anticancer Therapies Asia Congress 2025: Abstracts
The abstract submission is now open!
Related Articles
Relationships With Patients Imperative to AE Management in Cancer Care
Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.
LOAd703 Oncolytic Adenovirus Receives FDA Fast Track Designation for Pancreatic Cancer
LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.
LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment – The Cancer Letter
As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group…
ARANOTE Features Significant rPFS Benefit of Darolutamide/ADT in mHSPC
In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients with metastatic hormone-sensitive prostate cancer.
Blood Podcast | Blood | American Society of Hematology
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
Increased exercise tolerance in humanized G6PD-deficient mice
Key PointsG6PD-deficient mice maintain higher exercise speeds without increased red blood cell hemolysis, questioning assumed risks.Increased cardiac outpu
Expert Insights: Distinguishing between CARTITUDE-4 vs. KarMMa-3 Trials
Panelists discuss how the CARTITUDE-4 and KarMMa-3 trials differ in their patient populations, study designs, and outcomes, providing crucial insights for clinicians choosing between cilta-cel…
Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer
Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.
CRDC in Publications: How Are People Using the Available Resources? | CBIIT
The NCI Cancer Research Data Commons (CRDC) is a great resource for accessing cancer research data. So, how have your colleagues been using it recently?…
CheckMate-67T Trial Design
Panelists discuss the FDA approval of subcutaneous nivolumab based on the CheckMate-67T trial findings, highlighting its potential to improve patient convenience and treatment adherence while…